Predicting toxicities for patients with advanced gastrointestinal stromal tumours treated with imatinib: A study of the European Organisation for Research and Treatment of Cancer, the Italian Sarcoma Group, and the Australasian Gastro-Intestinal Trials Group (EORTC–ISG

Predicting toxicities for patients with advanced gastrointestinal stromal tumours treated with imatinib: A study of the European Organisation for Research and Treatment of Cancer, the Italian Sarcoma Group, and the Australasian Gastro-Intestinal Trials Group (EORTC–ISG–AGITG)

Published:2006-09 Issue:14 Volume:42 Page:2277-2285
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Glabbeke Martine Van,Verweij Jaap,Casali Paolo G.,Simes John,Cesne Axel Le,Reichardt Peter,Issels Rolf,Judson Ian R.,van Oosterom Allan T.,Blay Jean-Yves

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference24 articles.

1. Management of malignant gastrointestinal stromal tumours;Joensuu;Lancet Oncol,2002

2. for the EORTC Soft Tissue and Bone Sarcoma Group, the Italian Sarcoma Group and the Australasian Gastrointestinal Trials Group. Progression-free survival in gastrointestinal stromal tumours with high-dose imatininb: randomized trial;Verweij;Lancet,2004

3. Dose effect of imatinib in patients with metastatic GIST – Phase III sarcoma group study S0033;Rankin;J Clin Oncol,2004

4. European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study;van Oosterom;Lancet,2001

5. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors;Demetri;N Engl J Med,2002

Cited by 84 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Adverse effects of tyrosine kinase inhibitors in cancer therapy: pathophysiology, mechanisms and clinical management;Signal Transduction and Targeted Therapy;2023-07-07

2. Gene polymorphisms affect postoperative imatinib plasma levels and edema in adults with gastrointestinal stromal tumor;Pharmacogenomics;2023-05

3. Biological screening of a unique drug library targeting MRGPRX2;Frontiers in Immunology;2022-10-21

4. Clinical characteristics and outcomes of tyrosine kinase inhibitor-related lower GI adverse effects;Journal of Cancer Research and Clinical Oncology;2022-08-28

5. Genetic polymorphisms are associated with imatinib plasma levels and periorbital edema in Chinese patients with gastrointestinal stromal tumors receiving adjuvant imatinib;2022-08-26